Journal: bioRxiv
Article Title: Hypoimmunogenic hPSC-derived cardiac organoids for immune evasion and heart repair
doi: 10.1101/2025.04.09.648007
Figure Lengend Snippet: a-d, Bar charts of flow cytometry data showing expression of HLA-A2, HLA-BC, and HLA-E as percent positive expression in ( a ) hPSC-CMs, ( b ) hPSC-cFbs, ( c ) hPSC-ECs, and ( d ) hPSC-PCs by wild-type hPSC-derived cells (red) and UDET hPSC-derived cells (blue). e , Timeline of T cell cytotoxicity assay to measure T cell-mediated lysis of target cells. f-i , Percent lysis as quantified from LDH assay following exposure of activated CD8+ T cells to wild-type (red) and UDET (blue)-derived ( f ) hPSC-CMs, ( g ) hPSC-cFbs, ( h ) hPSC-ECs, and ( i ) hPSC-PCs. j , Timeline of NK cytotoxicity assay to measure NK cell-mediated lysis of target cells. k-n , Percent lysis as quantified from LDH assay following exposure of NK cells to wild-type (red) and UDET (blue)-derived ( k ) hPSC-CMs, ( l ) hPSC-cFbs, ( m ) hPSC-ECs, and ( n ) hPSC-PCs. Data shown from one donor representative of 2 biological replicates with 3-5 technical replicates. nd=no difference, *=p<0.05.
Article Snippet: Pre-conjugated antibodies used: B2M-APC (1:100; Biolegend, 316312, clone 2M2), HLA-A/B/C-PE (1:40; Biolegend, 311406, clone W6/32), HLA-E-APC (1:40; Biolegend, 342606, clone 3D12), HLA-G-APC (1:100; Biolegend, 335909, clone 87G), HLA-E-APC (1:50; Invitrogen, 17995342, clone 3D12HLA-E), HLA-BC-APC (1:50; Invitrogen, 17593542, clone B1.23.2), HLA-A2-PE-Cy7, clone BB7.2), CD25-APC (1:50; R&D Systems, FAB1020A, clone 24212), CD45-BV421 (1:50; Biolegend, 304032, clone HI30), CD3-BV605 (1:50; Biolegend, 344836, clone SK7), CD8-APC (1:50; Biolegend, 344722, clone SK1), CD4-PE (1:50; Biolegend, 980804, clone SK3).
Techniques: Flow Cytometry, Expressing, Derivative Assay, Cytotoxicity Assay, Lysis, Lactate Dehydrogenase Assay